Marks Gilbert Lynn 4

What Happened Marks Gilbert Lynn, a director of AN2 Therapeutics, was granted 20,400 derivative shares (award) on Feb 20, 2026. The grant shows an acquisition at $0.00 per share (total reported value $0) and is recorded as a derivative award rather than an open-market purchase or sale. The awarded shares will vest on February 20, 2027, subject to the reporting person providing continuous service through that date.

Key Details

• Transaction date: February 20, 2026; Form 4 filed February 23, 2026.
• Security/amount: 20,400 shares (derivative award) acquired at $0.00 per share (reported value $0).
• Vesting: Footnote states the shares vest on February 20, 2027, conditional on continuous service.
• Shares owned after transaction: Not specified in the provided filing summary.
• Filing timeliness: Form 4 was filed three days after the transaction date; the filing as provided does not include a late‑filing flag in the summary data shown here.

Context This is a compensation-related equity award (derivative grant) that does not represent an immediate open-market purchase or sale. Because the shares are subject to a one-year vesting condition, they are not yet vested or freely tradable; such awards are commonly used to align executive/director incentives with long-term company performance rather than signal near-term insider buying or selling.